biotech
Novo Nordisk Discontinues R&D on Small Molecules for Oral Treatment of Diabetes
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics , Genomics, Proteomics and Bioinformatics by ruth on January 23, 2007
Novo Nordisk Discontinues R&D on Small Molecules for Oral Treatment of Diabetes
Denmark-based biopharmaceutical firm Novo Nordisk will cease all its R&D programs in small molecules for the oral treatment of diabetes and will focus instead on its protein-based pharmaceuticals.
"Our core competences lie within therapeutic proteins, and it is within this area that we can make the greatest difference in terms of patient outcomes and company growth. Therefore, it is a logical move to focus all our research and development efforts on this area."

All existing projects on small molecules, including NN9101, a glucokinase activator currently in phase 1 clinical testing, may be out-licensed.

Source: Novo Nordisk

Permalink: Novo Nordisk Discontinues R&D on Small Molecules for Oral Treatment of Diabetes
Tags: novo+nordisk  small+molecules  diabetes  research  biotech  treatment+diabetes 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/50538
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Novo Nordisk Discontinues R&D on Small Molecules for Oral Treatment of Diabetes:

  • Currently 5.33/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 5.33 out of 3 vote(s) cast.
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!